Clinical Experience With Subcutaneous Efgartigimod PH20 in Patients With Newly Diagnosed Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Paulina Gutierrez-Trejo1, Raghav Govindarajan2
1University of Health Science and Pharmacy in St.Louis, 2HSHS St. Elizabeth Medical Group
Objective:
The objective of our study was to assess if once weekly efgartigimod PH20 SC is beneficial in a cohort of newly diagnosed treatment-naïve CIDP patients.
Background:
In ADHERE trial (NCT04281472), subcutaneous (SC) efgartigimod PH20 provided clinical benefit in participants with worsening chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), regardless of prior CIDP treatment. Experience with efgartigimod PH20 SC for CIDP in the clinical setting are limited.
Design/Methods:
Case series of five patients with typical CIDP who are diagnosed with CIDP between July 2024-January 2025. Ease of use was the reason for starting patients on efgartigimod PH20 SC in 3 patients and history of congestive heart failure in the other two.
Results:
Four patients met the CIPD criteria and one possible based on the 2021 EAN/PNS CIDP guidelines. Mean age 56.6 years and four were men. Mean INCAT before treatment (upper limb=2.75, lower limb=3.25, n=4). Mean MRC sum score before treatment 39.5 (n=4). Mean INCAT 2 months after treatment (upper limb=2.25, lower limb=2.25), at 4months (upper limb=1.75, lower limb=2), at 6 months (upper limb,1.5, lower limb= 1.75). Mean MRC at 2,4 and 6 months (n=4) were 43, 45 and 47.5. One patient deteriorated within a month after starting treatment with efgartigimod PH20 SC and was transitioned IVIg with significant improvement in INCAT and MRC sum score. Most common side effects were injection site reaction, urticaria and rash which resolved with repeated injections.
Conclusions:
4 out of 5 newly diagnosed treatment-naïve typical CIDP patients continued to respond to efgartigimod PH20 SC at the end of 6 months with minor local site reactions.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.